Recent study findings on intravenous lysis therapy with fibrinolytic agents

Intravenous thrombolysis, with or without mechanical thrombectomy, is a key pillar in the treatment of ischemic stroke. There are now two approved treatment options available—alteplase and tenecteplase—and Phase II data are available for reteplase. However, the use of intravenous thrombolysis in mild strokes is now controversial, as studies such as TRACE-III and ARAMIS have called into question the benefit-risk ratio in this patient population compared to the use of dual antiplatelet therapy.